Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2013 3
2014 3
2015 3
2017 1
2018 2
2019 3
2020 2
2021 1
2022 1
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials.
Gbadamosi MO, Shastri VM, Elsayed AH, Ries R, Olabige O, Nguyen NHK, De Jesus A, Wang YC, Dang A, Hirsch BA, Alonzo TA, Gamis A, Meshinchi S, Lamba JK. Gbadamosi MO, et al. Leukemia. 2022 Aug;36(8):2022-2031. doi: 10.1038/s41375-022-01622-0. Epub 2022 Jun 10. Leukemia. 2022. PMID: 35688939 Free PMC article.
Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin.
Short NJ, Richard-Carpentier G, Kanagal-Shamanna R, Patel KP, Konopleva M, Papageorgiou I, Pemmaraju N, Borthakur G, Ravandi F, DiNardo CD, Kadia TM, Kantarjian H, Lamba JK, Daver N. Short NJ, et al. Am J Hematol. 2020 Sep;95(9):E225-E228. doi: 10.1002/ajh.25854. Epub 2020 May 23. Am J Hematol. 2020. PMID: 32356320 Free article. No abstract available.
ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children's Oncology Group AAML0531 Trial.
Rafiee R, Chauhan L, Alonzo TA, Wang YC, Elmasry A, Loken MR, Pollard J, Aplenc R, Raimondi S, Hirsch BA, Bernstein ID, Gamis AS, Meshinchi S, Lamba JK. Rafiee R, et al. Blood Cancer J. 2019 May 21;9(6):51. doi: 10.1038/s41408-019-0211-y. Blood Cancer J. 2019. PMID: 31113932 Free PMC article. Clinical Trial.
CCGG deletion (rs201074739) in CD33 results in premature termination codon and complete loss of CD33 expression: another key variant with potential impact on response to CD33-directed agents.
Papageorgiou I, Loken MR, Brodersen LE, Gbadamosi M, Uy GL, Meshinchi S, Lamba JK. Papageorgiou I, et al. Leuk Lymphoma. 2019 Sep;60(9):2287-2290. doi: 10.1080/10428194.2019.1569232. Epub 2019 Feb 5. Leuk Lymphoma. 2019. PMID: 30721105 Free PMC article. No abstract available.
CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.
Lamba JK, Chauhan L, Shin M, Loken MR, Pollard JA, Wang YC, Ries RE, Aplenc R, Hirsch BA, Raimondi SC, Walter RB, Bernstein ID, Gamis AS, Alonzo TA, Meshinchi S. Lamba JK, et al. J Clin Oncol. 2017 Aug 10;35(23):2674-2682. doi: 10.1200/JCO.2016.71.2513. Epub 2017 Jun 23. J Clin Oncol. 2017. PMID: 28644774 Free PMC article. Clinical Trial.
Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy.
Mortland L, Alonzo TA, Walter RB, Gerbing RB, Mitra AK, Pollard JA, Loken MR, Hirsch B, Raimondi S, Franklin J, Pounds S, Cao X, Rubnitz JE, Ribeiro RC, Gamis A, Meshinchi S, Lamba JK. Mortland L, et al. Clin Cancer Res. 2013 Mar 15;19(6):1620-7. doi: 10.1158/1078-0432.CCR-12-3115. Epub 2013 Feb 26. Clin Cancer Res. 2013. PMID: 23444229 Free PMC article.
Valproic acid pathway: pharmacokinetics and pharmacodynamics.
Ghodke-Puranik Y, Thorn CF, Lamba JK, Leeder JS, Song W, Birnbaum AK, Altman RB, Klein TE. Ghodke-Puranik Y, et al. Pharmacogenet Genomics. 2013 Apr;23(4):236-41. doi: 10.1097/FPC.0b013e32835ea0b2. Pharmacogenet Genomics. 2013. PMID: 23407051 Free PMC article. No abstract available.
PharmGKB summary: zidovudine pathway.
Ghodke Y, Anderson PL, Sangkuhl K, Lamba J, Altman RB, Klein TE. Ghodke Y, et al. Pharmacogenet Genomics. 2012 Dec;22(12):891-4. doi: 10.1097/FPC.0b013e32835879a8. Pharmacogenet Genomics. 2012. PMID: 22960662 Free PMC article. No abstract available.